Table 2.

Next-generation ALK inhibitors

Next-generation ALK inhibitors	Manufacturer	Approval status	Ongoing trials
Alectinib	Genentech	Approved	Phase 3 study of alectinib versus crizotinib in treatment-naive patients [NCT02075840]
Brigatinib	Ariad	Breakthrough Therapy Designation*	Phase 1/2 study of brigatinib [NCT01449461] Phase 2 randomised study testing two doses of brigatinib in patients previously treated with crizotinib (ALTA) [NCT02094573] Phase 3 study of brigatinib versus crizotinib in ALK inhibitor-naive patients (ALTA-1L) [NCT02737501]
Ceritinib	Pfizer	Approveda,b	Phase 2 study of ceritinib in crizotinib-naive patients [NCT01685138] Phase 3 study of ceritinib versus chemotherapy in treatment-naive patients [NCT01828099] Phase 3 study of ceritinib versus chemotherapy in patients previously treated with chemotherapy and crizotinib [NCT01828112]
Ensartinib	Xcovery	Investigational	Phase 1/2 study of ensartinib in patients with advanced solid tumors [NCT01625234]
Entrectinib	Ignyta	Investigational	Phase 1/2a study of entrectinib in patients with advanced solid tumors harboring NTRK, ROS1, or ALK alterations [NCT02097810] Phase 2 basket study of entrectinib in patients with solid tumors harboring NTRK, ROS1, or ALK rearrangements [NCT02568267]
Lorlatinib	Pfizer	Investigational	Phase 1/2 Study of lorlatinib in patients with ALK or ROS-rearranged lung cancer [NCT01970865]

ALK, anaplastic lymphoma kinase, ^aApproved by the United States Food and Drug Administration, ^bApproved by the European Medicines Agency.